Is This the End of the Cisplatin Eligibility Era in Muscle-invasive Bladder Cancer? Letter in reference to: Matthew D. Galsky, Begoña P. Valderrama, Marco Maruzzo, et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N Engl J Med 2026;395:338-48. doi:10.1056/NEJMoa2601486; and Galsky MD, Hahn NM, Rosenberg J, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 2011;12:211-214. doi:10.1016/S1470-2045(10)70275-8.

IF 25.2

European urology Pub Date : 2026-09-18 DOI:10.1016/j.eururo.2026.08.019

Patrizia Giannatempo, Linda Cerbone, Fabio Calabrò

引用次数: 0

肌浸润性膀胱癌顺铂适格时代结束了吗？信中提到：Matthew D. Galsky, Begoña P. Valderrama， Marco Maruzzo等人。顺铂适格的膀胱癌中，安替妥单抗和派姆单抗。中华医学杂志[J]; 2009; 31(5): 368 - 368。doi: 10.1056 / NEJMoa2601486;Galsky MD, Hahn NM， Rosenberg J等。转移性尿路上皮癌患者不适合顺铂化疗的共识定义。中华医学杂志2011；12:211-214。doi: 10.1016 / s1470 - 2045(10) 70275 - 8。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European urology

自引率

0.00%

发文量